Therapy-related acute promyelocytic leukemia: Observations relating to APL pathogenesis and therapy

European Journal of Haematology

Volumn 88, Issue 3, 2012, Pages 237-243

  Elliott, Michelle A ^a   Letendre, Louis ^a   Tefferi, Ayalew ^a   Hogan, William J ^a   Hook, Christopher ^a   Kaufmann, Scott H ^a   Pruthi, Rajiv K ^a   Pardanani, Animesh ^a   Begna, Kebede H ^a   Ashrani, Aneel A ^a   Wolanskyj, Alexandra P ^a   Al Kali, Aref ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute promyelocytic leukemia; Body mass index; Treatment related

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; GEMTUZUMAB; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HYPERLIPIDEMIA; LEUKEMOGENESIS; LIPID METABOLISM; LUNG CARCINOMA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CARCINOMA; THERAPY RELATED ACUTE PROMYELOCYTIC LEUKEMIA; THERAPY RELATED PROMYELOCYTIC LEUKEMIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RADIOTHERAPY; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856958854     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01727.x     Document Type: Article

References (27)

1. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137-46.
2. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116:3171-9.
3. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-38.
4. Mays AN, Osheroff N, Xiao Y, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010;115:326-30.
5. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-37.
6. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11:1661-4.
7. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology 2006;1:162-8.
8. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010;116:3751-7.
9. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972-6.
10. Dayyani F, Kantarjian H, O'Brien S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011;117:110-5.
11. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53.
12. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120:278-86.
13. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009;113:775-83.
14. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.
15. Thomas X, Fiere D, Archimbaud E. Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia. Leukemia 1998;12:1503-6.
16. Laharrague P, Larrouy D, Fontanilles AM, et al. High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J 1998;12:747-52.
17. Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999;93:1668-76.
18. Tabe Y, Konopleva M, Munsell MF, et al. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004;103:1815-22.
19. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
20. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137-45.
21. Cervera J, Montesinos P, Hernandez-Rivas JM, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 2010;95:424-31.
22. Ono T, Takeshita A, Iwanaga M, Asou N, Naoe T, Ohno R. Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. Haematologica 2011;96:174-6.
23. Ravandi F. Therapy-related acute promyelocytic leukemia. Haematologica 2011;96:493-5.
24. Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011;96:621-5.
25. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5.
26. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504-10.
27. Montesinos P, Gonzalez JD, Gonzalez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 2010;28:3872-9.